$0.26
15.78% today
Nasdaq, Apr 04, 09:16 pm CET
ISIN
US52187K1016
Symbol
LPTX
Sector
Industry

Leap Therapeutics, Inc. Stock price

$0.31
-0.11 25.71% 1M
-2.16 87.27% 6M
-2.56 89.06% YTD
-2.22 87.57% 1Y
-18.79 98.35% 3Y
-13.89 97.79% 5Y
-78.29 99.60% 10Y
Nasdaq, Closing price Thu, Apr 03 2025
-0.03 7.53%
ISIN
US52187K1016
Symbol
LPTX
Sector
Industry

Key metrics

Market capitalization $12.97m
Enterprise Value $-34.01m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF 0.56
P/B ratio (TTM) P/B ratio 0.34
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-70.06m
Free Cash Flow (TTM) Free Cash Flow $-60.30m
Cash position $47.25m
EPS (TTM) EPS $-1.84
Short interest 4.77%
Show more

Is Leap Therapeutics, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,794 stocks worldwide.

Leap Therapeutics, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

2 Analysts have issued a Leap Therapeutics, Inc. forecast:

1x Buy
50%
1x Hold
50%

Analyst Opinions

2 Analysts have issued a Leap Therapeutics, Inc. forecast:

Buy
50%
Hold
50%

Financial data from Leap Therapeutics, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
- -
-
100%
- Direct Costs 0.01 0.01
98% 98%
-
-0.01 -0.01
98% 98%
-
- Selling and Administrative Expenses 13 13
1% 1%
-
- Research and Development Expense 57 57
22% 22%
-
-70 -70
19% 19%
-
- Depreciation and Amortization 0.01 0.01
98% 98%
-
EBIT (Operating Income) EBIT -70 -70
20% 20%
-
Net Profit -68 -68
17% 17%
-

In millions USD.

Don't miss a Thing! We will send you all news about Leap Therapeutics, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Leap Therapeutics, Inc. Stock News

Neutral
Seeking Alpha
4 days ago
Leap Therapeutics (NASDAQ:LPTX ) Conference Call to discuss Updated Data from Part B of the DeFianCe Study March 26, 2025 8:00 AM ET Company Participants Douglas Onsi - President and CEO Cyndi Sirard - Chief Medical Officer Jason Baum - Chief Scientific Officer Conference Call Participants Matthew Pipps - William Blair Swayampakula Ramakanth - H.C. Wainwright Operator Good morning.
Neutral
PRNewsWire
9 days ago
Leap to host a conference call to present updated CRC clinical data today, March 26, 2025, at 8:00 a.m. ET CAMBRIDGE, Mass.
Neutral
PRNewsWire
9 days ago
Updated data confirms statistically significant 32% higher ORR and 3.5 month longer PFS  in second-line CRC patients with high DKK1 levels treated with sirexatamab plus bevacizumab and chemotherapy Statistically significant 22% higher ORR and 2.6 month longer PFS in patients who had not had prior anti-VEGF therapy Leap to host a conference call to present clinical data today, March 26, 2025, at...
More Leap Therapeutics, Inc. News

Company Profile

Leap Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in developing novel therapies designed to treat patients with cancer. Its clinical stage programs are DKN-01, which is a monoclonal antibody that inhibits Dickkopf-related protein 1, or DKK1 and TRX518, which is a monoclonal antibody targeting the glucocorticoid-induced tumor necrosis factor-related receptor, or GITR. The company was founded on January 3, 2011 and is headquartered in Cambridge, MA.

Head office United States
CEO Doug Onsi
Employees 52
Founded 2011
Website www.leaptx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today